Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However, their specificity to only target G12C mutations, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike.

The Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C.